- Target
- CD19 / BCMA
- Rights
- Global
Multiple MyelomaIIT
China: IIT
- Investigational candidates
- 8
- Program groups
- 3
Development by program
Filter by program and select a candidate to read its clinical overview.
As of
8 candidatesChinaUS
| Product | Target | Indication | DiscoveryPre-clinicalIITIND / Phase IPhase II | Status | Rights |
|---|---|---|---|---|---|
| In vivo CAR-T | |||||
| CD19 / BCMA | Multiple Myeloma | China | IIT | Global | |
| CD19 / BCMA | Multiple Myeloma / Autoimmune Diseases | China US | FDA clinical trial clearance | Global | |
| CD19 | Autoimmune Diseases | China | Q1 2027 FPI planned | Global | |
| CD19 / CD20 | B-NHL / B-ALL | China | Q1 2027 FPI planned | Global | |
| Undisclosed | Solid Tumor | China | Q1 2027 FPI planned | Global | |
| Ex vivo Allogeneic CAR-T | |||||
| CD19 / BCMA | Refractory SLE | China US | Phase 2a | Global | |
| AIHA | China | Phase 2a | |||
| Multiple Sclerosis | China | IIT | |||
| Ex vivo Allogeneic CAR-T (LD-free/less) | |||||
| CD19 / BCMA | Refractory SLE | China US | Phase 1 | Global | |
| CD19 / BCMA | SLE & MS | China | IIT | Global | |
In vivo CAR-T
- Target
- CD19 / BCMA
- Rights
- Global
Multiple Myeloma / Autoimmune DiseasesFDA clinical trial clearance
China: IND / Phase I · US: IND / Phase I
- Target
- CD19
- Rights
- Global
Autoimmune DiseasesQ1 2027 FPI planned
China: Pre-clinical
- Target
- CD19 / CD20
- Rights
- Global
B-NHL / B-ALLQ1 2027 FPI planned
China: Pre-clinical
- Target
- Undisclosed
- Rights
- Global
Solid TumorQ1 2027 FPI planned
China: Pre-clinical
Ex vivo Allogeneic CAR-T
- Target
- CD19 / BCMA
- Rights
- Global
Refractory SLEPhase 2a
China: Phase II · US: Phase II
FTD, RMAT, BTD (SLE-ITP)AIHAPhase 2a
China: Phase II
Multiple SclerosisIIT
China: IIT
Ex vivo Allogeneic CAR-T (LD-free/less)
- Target
- CD19 / BCMA
- Rights
- Global
Refractory SLEPhase 1
China: IND / Phase I · US: IND / Phase I
- Target
- CD19 / BCMA
- Rights
- Global
SLE & MSIIT
China: IIT
These product candidates are investigational and are not approved for commercial use. Development plans are subject to change.
Abbreviations
SLE: Systemic lupus erythematosus · AIHA: Autoimmune hemolytic anemia · MS: Multiple sclerosis · LD: Lymphodepletion · B-NHL: B-cell non-Hodgkin lymphoma · B-ALL: B-cell acute lymphoblastic leukemia · IIT: Investigator-initiated trial · IND: Investigational new drug · FPI: First patient in · FTD: Fast Track Designation · RMAT: Regenerative Medicine Advanced Therapy · BTD: Breakthrough Therapy Designation
Genome editing
The genome editing behind our pipeline
Pioneer in Genome Editing
Pioneered the new generation of gene-editing technology, CRISPR, and demonstrated for the first time that genome editing is possible in human and other mammalian cells.
62 genes knocked out in a single cell
Multiplex gene knockout
62 genes in a single cell were successfully knocked out with the gene-editing tool.
Multiple transgene knock-ins
Our research uses multiple transgene knock-ins to study durable in vivo expression.
Immune privilege
Multiplex genome editing supports our research into immune-privileged cells and organs for transplantation.
Immune privilege platform
Research into immune-privileged cells and organs
Our immune privilege research combines genome engineering and transplantation immunology to study how cells and organs may resist rejection. We are exploring natural killer cells for immuno-oncology and cardiomyocytes, neurons and islet cells for regenerative medicine. Our xenotransplantation research studies gene-edited donor animals as a potential source of transplantable cells, tissues and organs.
Immune responses under study
- Macrophage
- T Cell
- Antibody
- NK Cell
- B Cell
- Inflammatory Cell
Other applications
Besides cell and organ therapies, we also apply our multiplex genome-editing technology to other applications, such as producing animals with enhanced agronomical traits or multi-disease resistance in agriculture.